search
EN
中
Current Location：Home About QyunsCompany Profile

Company Profile

Adhering to the vision of "innovation for the great majority", Qyuns Therapeutics focuses on the research and development, industrialization and commercial expansion of antibody drugs in the fields of autoimmune and allergic diseases, and strives to solve the problems of drug accessibility and affordability.

Based on our complete independent innovation capabilities, the company has formed a innovative pipeline, of which 6 pipelines are in the clinical trial stage, with indications covering the four major diseases such as skin, respiratory, digestive, and rheumatism. We have built one of the most comprehensive pipelines in autoimmune and allergic diseases in terms of the number of IND-approved drug candidates and indications, which was also one of the most advanced in terms of the overall development status among Chinese domestic companies.  Through the forward-looking input of production end and sales end, the company continues to strengthen the certainty of development.

Qyuns Therapeutics, as a national high-tech enterprise, has applied for more than 70 invention patents domestic and overseas. It has also been recognized as a potential unicorn enterprise by Productivity Centre of Jiangsu Province.


Mission

“ To pursue scientific innovation and deliver affordable and quality therapeutics ”

To achieve this mission, Qyuns continues to advance its research and development process and expand its product pipeline through independent innovation, forward-looking industrial input, and diversified collaboration. To make innovation sustainable, make patients affordable, and make drugs more accessible!

Advantages and Strategies

Our Strengths
01
Exclusive focus on autoimmune and allergic diseases, with comprehensive coverage of four major disease areas and deep knowledge of key therapeutic pathways;
02
One of China’s most comprehensive and advanced pipelines of biologics in autoimmune and allergic diseases;
03
Commercial-scale in-house manufacturing capacity ensuring stable and costcontrollable supply of our products;
04
Practical commercialization model leveraging strategic partnership to secure early product launch;
05
A visionary management team with rich industry experience and successful entrepreneurial track records.
Our Strategy
01
Build leadership in dermatology, advance other drug candidates and strategically expand our pipeline;
02
Continue to optimize CMC quality management system and improve production efficiency and enhance manufacturing capacity utilization;
03
Collaborate with potential partners in commercialization;
04
Explore international expansion opportunities;
05
Continue to recruit and develop talent.

Company History

Never stop on innovation and exploration
  • 2023
  • 2022
  • 2021
  • 2020
  • 2019
  • 2018
  • 2016
  • 2015

  • Completed the Phase Ib clinical trial of QX005N for the treatment of AD in China.

    Completed subject enrollment for our Phase II clinical trial of QX005N for the treatment of AD in China.

    Commenced a Phase II clinical trial in adult patients with PN in China for QX005N for the treatment of PN.

    Completed the Phase Ia clinical trial of QX005N in healthy subjects in China.

    Built joint laboratory with China Pharmaceutical University.

  • Won awards from multiple authoritative institutions in the industry.

    Awarded as a potential unicorn enterprise in Jiangsu Province for three consecutive years.

    The Phase III clinical trial of QX001S for the treatment of Ps in China reached its primary endpoint.

    Initiated the Phase II clinical trial of QX002N for the treatment of AS in China and completed patient enrollment.

    Received an IND approval from FDA for QX008N for the treatment of severe asthma.

    Received IND approval from the NMPA for QX008N for the treatment of asthma and for the treatment of moderate-to-severe COPD.

    Received IND approvals from the NMPA for QX005N for the treatment of CSU, the treatment of PN and the treatment of moderate-to-severe asthma.

    Received IND approval from NMPA for QX004 for the treatment of Crohn’s disease.

    Obtained National High tech Enterprise Certificate.

    Closed series C round funding and raised RMB227.5 million.

    Approved to build Jiangsu Provincial Immune Disease Antibody Engineering Research Cente.

  • Completion of shareholding system reform.

    Received IND approval from the NMPA for QX005N for the treatment of CRSwNP.

    Received IND approval from the NMPA for QX006N for the treatment of SLE.

    Received IND approval from the NMPA for QX004N for the treatment of Ps.

    Completed the Phase Ia clinical trial of QX002N for the treatment of AS in China.

    Closed series B++ round funding and raised RMB300 million.

  • Closed series B+ round funding and raised RMB370 million.

    Entered into a collaboration agreement with Zhongmei Huadong with respect to the joint development and commercialization of QX001S in China.

    Closed series B round financing and raised RMB230 million.

    Received IND approval of QX005N from the NMPA for the treatment of moderate-to-severe AD in adults in China.

    Completed the Phase I clinical trial of QX001S for the treatment of Ps in China.

  • Received IND approval of QX002N from the NMPA for the treatment of active AS in adults in China.

  • Cellularforce, our CMC-focused subsidiary, was established in Taizhou.

    Received IND approval of QX001S from the NMPA for the treatment of moderate-to-severe plaque Ps in China.

  • Closed series A round financing and raised RMB120 million.

  • Closed series Pre-A round financing and raised RMB14 million.

    Founded in China Medical City (Taizhou).